AUTH/3476/2/21: Anonymous (contactable) v Leo Pharma – LinkedIn profile allegations (No breach after appeal)

📅 2021 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3476/2/21
PartiesAnonymous, contactable complainant v Leo Pharma
IssueAlleged Code breaches arising from a Leo employee’s LinkedIn profile (qualification claim; references to Innohep and Picato; “switch” wording; “safe” wording; alleged promotion to public/HCPs; alleged lack of prescribing information/certification)
Medicines mentionedInnohep; Picato (ingenol mebutate)
Applicable Code year2019
Complaint received9 February 2021
Case completed18 November 2021
Panel outcomeInitially ruled some breaches (later appealed)
Appeal outcomeAppeal successful; all breaches overturned; no breach of the Code
Additional sanctionsNone

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A contactable complainant challenged statements on a named Leo Pharma medical department employee’s publicly viewable LinkedIn profile (open privacy settings alleged), including claimed qualifications and descriptions of past roles/achievements.
  • The complainant alleged the profile content amounted to promotion of prescription-only medicines (notably Innohep) to the public and to health professionals, without prescribing information and without certification.
  • The complainant also alleged the profile implied prohibited “switch services” ("Gained a complete switch to Innohep…"), off-licence promotion/training, and inappropriate use of the word “safe”.
  • Statements about Picato (ingenol mebutate) and actinic keratosis were also alleged to be promotional and non-compliant.
  • Leo responded that the LinkedIn content was essentially an online CV (copied from the employee’s CV), intended for recruitment, and not promotional; Leo also provided evidence the employee’s qualification was authentic.
  • The Panel initially ruled some breaches (notably around Innohep references and the word “safe”), but Leo appealed.
  • The Appeal Board distinguished between LinkedIn “Activity” (posts/shares) and the “Experience” section (CV-style content requiring active searching/clicks), and overturned all breaches.
⚖️

Outcome

  • Final decision: No breach of the Code (Appeal Board upheld Leo’s appeal and overturned the Panel’s breach rulings).
  • The Appeal Board stated it was uncomfortable with some of the language used and asked that Leo be advised of its concerns, but it did not find Code breaches.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training